All
12 December 2022
Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating its lead immunotherapy, EO2401, in recurrent glioblastoma
Enterome, a clinical stage company developing first-in-class immunomodulatory drugs based on its gut bacterial Mimicry drug discovery platform, today announces completion of...
7 December 2022
Enterome presents two posters on Phase 2 data of its lead immunotherapy, EO2401, in recurrent glioblastoma (ROSALIE study) at ESMO IO 2022
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its gut bacterial Mimicry drug discovery platform, today...
16 November 2022
Enterome announces presentation of data from ongoing Phase 1/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022
Enterome announces it will present updated efficacy, immunogenicity and safety data from its Phase 1/2 trial of EO2401 in combination with nivolumab +/- bevacizumab, in...
11 November 2022
SITC oral presentation yesterday by Dr Reardon / update on EO2401 ROSALIE study in rGBM
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces...
7 November 2022
MaaT Pharma Announces Participation in Scientific and Investor Conferences in November
MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients...
17 October 2022
Clinical Microbiomics adds metabolomics to its portfolio with acquisition of MS-Omics to form the leading multi-omics provider for the microbiome field.
Clinical Microbiomics, a pioneering microbiome research
company, today announced its acquisition of MS-Omics, a leading metabolomics provider
based in Denmark.
11 October 2022
Clinical Microbiomics set to accelerate its expansion with EUR 10 million investment from Health for Life Capital™ II” managed by Seventure Partners
Seventure Partners, a worldwide leading microbiome venture capital, and Clinical Microbiomics A/S, a pioneering microbiome research company, today announced the completion of a...
14 September 2022
Foodtech startup STANDING OVATION closes a €12M Series A financing round to accelerate the development of its animal-free casein and cheese substitute production process
STANDING OVATION, a player in the food transition, announced today a Series A financing round of €12 million led by Astanor Ventures, with the participation of Peakbridge,...